Yarrow Bioscience Inc (NASDAQ: YARW) is a Healthcare company (Biotechnology) with a market capitalization of $134M. The Maz Rating grades it against the other companies in its sector.
Yarrow Bioscience Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $14.21, Yarrow Bioscience Inc trades at 427.6x sales and 1.2x book value, with an EV/EBITDA of 6.5. Over the last twelve months it generated about $313662 of revenue and a net loss of $145M. It runs a gross margin of 96.2%, an operating margin of -7309.9% and a net margin of -6758.1%. It shows return on equity of -24.7%, return on invested capital of -8.6% and a free cash flow yield of -75.4%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 42.08. Over the past 52 weeks the share price ranged from $12.38 to $46.95, with a beta of 2.13.
Yarrow Bioscience Inc pays a dividend yielding 141.75%.
1 Wall Street analyst rating covers the stock: 1 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.